CRISPR Therapeutics AG (CRSP) insider trading
Every open-market stock purchase and sale by CRISPR Therapeutics AG executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Samarth Kulkarni (CEO) and 3 others sold $4.9M in the last 90 days.
- Last insider buy: Douglas A Treco (Insider), $1.1M, 15 months ago.
Last 12 months: insiders bought $0 (0 buys) and sold $17.9M (23 sales). Last close $50.50 on Oct 21, 2026.
Recent CRSP insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Oct 19, 2026 | Samarth Kulkarni (CEO) | Sold | $2.4M |
| Oct 19, 2026 | Andrew Jacob Silver (CFO) | Bought (not open market) | — |
| Oct 16, 2026 | Samarth Kulkarni (CEO) | Bought (not open market) | — |
| Oct 16, 2026 | Samarth Kulkarni (CEO) | Bought (not open market) | — |
| Oct 14, 2026 | Simeon George (Insider) | Sold | $720K |
| Oct 14, 2026 | Simeon George (Insider) | Bought (not open market) | $420K |
| Oct 14, 2026 | Samarth Kulkarni (CEO) | Sold | $202K |
| Oct 14, 2026 | James R. Kasinger (General Counsel) | Sold | $51.2K |
| Oct 14, 2026 | Simeon George (Insider) | Bought (not open market) | — |
| Oct 13, 2026 | Samarth Kulkarni (CEO) | Bought (not open market) | — |
| Oct 13, 2026 | James R. Kasinger (General Counsel) | Bought (not open market) | — |
| Oct 13, 2026 | James R. Kasinger (General Counsel) | Bought (not open market) | — |
| Oct 13, 2026 | Samarth Kulkarni (CEO) | Bought (not open market) | — |
| Oct 6, 2026 | James R. Kasinger (General Counsel) | Sold | $119K |
| Oct 6, 2026 | James R. Kasinger (General Counsel) | Bought (not open market) | $27.1K |
| Oct 6, 2026 | James R. Kasinger (General Counsel) | Bought (not open market) | — |
| Sep 22, 2026 | James R. Kasinger (General Counsel) | Sold | $626K |
| Sep 22, 2026 | James R. Kasinger (General Counsel) | Bought (not open market) | $142K |
| Sep 22, 2026 | James R. Kasinger (General Counsel) | Bought (not open market) | — |
| Sep 17, 2026 | Ali Behbahani (Insider) | Sold | $781K |
| Sep 17, 2026 | Ali Behbahani (Insider) | Bought (not open market) | $420K |
| Sep 17, 2026 | Ali Behbahani (Insider) | Bought (not open market) | — |
| Aug 7, 2026 | Raju Prasad (CFO) | Sold (not open market) | — |
| Jun 5, 2026 | Katherine A High (Insider) | Bought (not open market) | — |
| Jun 5, 2026 | John Greene (Insider) | Bought (not open market) | — |
Who's trading CRSP
- Andrew Jacob Silver, CFO: other filings, last Oct 19, 2026
- Samarth Kulkarni, CEO: sold $9.6M (9 sales), last Oct 19, 2026
- Simeon George, Insider: sold $720K (1 sale), last Oct 14, 2026
- James R. Kasinger, General Counsel: sold $1.4M (7 sales), last Oct 14, 2026
- Ali Behbahani, Insider: sold $781K (1 sale), last Sep 17, 2026
- Raju Prasad, CFO: sold $5.1M (10 sales), last Aug 7, 2026
- Katherine A High, Insider: other filings, last Jun 5, 2026
- Harold Edward Fleming, Insider: other filings, last Jun 5, 2026
- Maria Fardis, Insider: other filings, last Jun 5, 2026
- Sandesh Mahatme, Insider: other filings, last Jun 5, 2026
- Briggs Morrison, Insider: other filings, last Jun 5, 2026
- Douglas A Treco, Insider: other filings, last Jun 5, 2026
- Christian Rommel, Insider: other filings, last Jun 5, 2026
- John Greene, Insider: other filings, last Jun 5, 2026
- Naimish Patel, C-suite exec: sold $363K (2 sales), last May 29, 2026
Get free alerts when an insider at CRISPR Therapeutics AG files a new trade →